U.S. Transportation Stock News

Earlier this month, Tilray Brands expanded its hemp-derived Delta-9 THC beverage portfolio by launching new 10mg format drinks under the Fizzy Jane's and Happy Flower brands, now available online and across retail markets in 10 states. This development marks a significant step for Tilray Brands into higher-dosage beverage offerings, broadening consumer choice and expanding distribution reach in the U.S. hemp beverage category. We'll explore how the entry into the 10mg THC beverage segment...

Earlier this week, Exponent reported revenues that narrowly exceeded analyst expectations but issued revenue guidance for the coming quarter that landed just below forecasts. This cautious outlook, and the company’s persistently high price-to-earnings ratio despite tepid earnings growth, has drawn attention to concerns about the sustainability of Exponent’s valuation given current performance trends. We'll explore how Exponent's softer revenue guidance and muted growth outlook may reshape...

If you are wrestling with what to do about W.W. Grainger stock right now, you are not alone. Investors have watched Grainger’s shares move sideways and then downward lately, with the price dropping slightly over the past month and a pullback of over 7% in the last 90 days. Yet, when viewed from a longer-term perspective, the story brightens. The stock has delivered a solid 2.6% total return over the past year and has more than doubled over five years. Clearly, this is not a sleepy industrial...

Ares Management (ARES) has caught investor attention again this week, though not for a specific breaking event or dramatic headline. Instead, the stock’s recent moves have many asking themselves whether this quiet period is actually a signal. Perhaps the market is just taking a breather before its next decisive step. For long-term shareholders and those watching from the sidelines, it raises that ever-present question: are we missing something right in front of us? If you zoom out, Ares...

On August 20, 2025, AeroVironment announced the successful delivery and integration of its new P550 small Unmanned Aircraft Systems to the U.S. Army as part of the Long-Range Reconnaissance program, accompanied by comprehensive operator training and support for rapid deployment. This marks a foundational step in the U.S. Army's adoption of modular, AI-enabled UAS platforms, which offer adaptability and long-term upgrade potential for evolving defense needs. We’ll examine how the successful...

Fluence Energy, Inc. ( NASDAQ:FLNC ) shares have retraced a considerable 33% in the last month, reversing a fair amount...

The recent surge in Charles Schwab (SCHW) shares might have caught your eye, especially if you’re wondering whether it’s a fleeting bounce or something more. There hasn’t been a single headline-grabbing event lighting up the news feed. However, the quiet momentum in Schwab’s stock has fueled plenty of back-and-forth among investors. It’s the kind of move that doesn’t demand urgency but definitely calls for a closer look at what might be unfolding beneath the surface. Stepping back, Schwab’s...

Recently, SLM reported that its short percent of float increased by 18.42% since the previous update, with 8.78 million shares now sold short, representing 4.95% of its available trading shares and an average of 3.84 days to cover these positions based on trading volume. This shift suggests traders are increasingly expecting downward movement in SLM's share price, which can influence investor sentiment and trading behavior. We'll explore how the recent rise in short interest could influence...

If you have been watching Elevance Health (ELV) lately, the stock’s recent slide might pique your curiosity. Shares have drifted lower, closing just under $310, and while there is no single headline driving this move, the change in direction comes as investors weigh the company’s longer-term prospects against current performance. Even with steady revenue and net income growth in the past year, the market’s sentiment appears to be shifting. Looking beyond this month’s nearly 10% gain, Elevance...

Key Insights Significantly high institutional ownership implies AppFolio's stock price is sensitive to their trading...

If you are sitting on the fence about what to do with Parker-Hannifin stock, you are not alone. After a string of strong performances over the past year, many investors are trying to decide whether PH still has room to run, or if it is time to take some profits off the table. The past 12 months have treated shareholders well, with a total return of 26.1%. Even more impressive, the stock has more than doubled over the last three years, rewarding long-term holders who believed in the company's...

Thinking about what to do with Williams-Sonoma stock? You are not alone. Even seasoned investors have been keeping a closer eye on WSM, especially after the impressive run over the last year. The stock’s recent performance tells quite the story. It is up roughly 53% over the past twelve months and has more than tripled over the past five years. That kind of growth is hard to ignore, and it has left many wondering whether Williams-Sonoma is still a buy or if it is time to lock in gains. Over...

After Dole (NYSE:DOLE) released its second quarter results, investors found themselves with plenty to digest. The company topped expectations on both revenue and adjusted profit, driven mainly by growth in its Diversified Fresh Produce and Fresh Fruit segments. Management’s decision to complete the sale of the Fresh Vegetable division also signals a clearer focus on areas where Dole sees the highest returns. Additionally, the push toward debt reduction reflects a more cautious, long-term...

Thinking about what to do with Arista Networks stock? You are not alone. As the tech landscape keeps shifting, ANET has caught the eye of many investors who are weighing growth potential against already hefty price gains. Over the past year, Arista Networks has delivered a remarkable 50% total return, with gains stacking up to more than 800% over the last five years. These numbers are enough to make anyone sit up and wonder whether the ride is just getting started or if this rocket ship has...

Akso Health Group recently announced its full year financial results for the period ended March 31, 2025, reporting sales of US$14.78 million and a net loss of US$134.98 million, alongside a basic and diluted loss per share of US$0.48. In addition, the company’s auditor expressed doubt about Akso Health Group’s ability to continue as a going concern in its latest annual filing, highlighting financial sustainability risks despite the growth in reported revenue. We’ll examine what the...

If you are weighing whether to jump into Royalty Pharma or considering if it is time to take some profits, you are not alone. This stock has become a topic of lively debate, especially as its recent run has caught the attention of both cautious and opportunistic investors. Over the past year, Royalty Pharma has delivered a total return of over 34%. What really stands out is its nearly 41% surge year-to-date. While its five-year numbers are barely in the red, the short-term momentum is...

Thinking about what to do with Boston Scientific stock? You are not alone. With the company’s shares up an impressive 17.7% year-to-date and a remarkable 32.2% over the past year, it is no wonder many investors are wondering if there is still room to grow, or if it is time to take some profits off the table. The stock’s five-year run, delivering an eye-catching 157.9% total return, speaks to strong momentum. However, this also raises questions about whether that growth is justified or coming...

Earlier this month, Cadence announced a breakthrough collaboration with NVIDIA to enable hardware-accelerated dynamic power analysis of billion-gate AI chip designs using the Palladium Z3 Enterprise Emulation Platform and Dynamic Power Analysis App. This development significantly improves the efficiency and accuracy of pre-silicon power modeling for AI and GPU-accelerated systems, addressing longstanding scalability challenges faced by semiconductor designers. We'll explore how this...

Key Insights The considerable ownership by individual investors in Richtech Robotics indicates that they collectively...

Oceaneering International announced that its Marine Services Division was awarded an indefinite-delivery/indefinite-quantity contract by the Naval Supply Systems Command Weapon Systems Support, worth up to US$86 million over two years with three additional option years, to repair valves and actuators for U.S. Navy Virginia-class and Los Angeles-class submarines. This contract highlights Oceaneering’s expanding role in U.S. defense logistics, adding multi-year revenue visibility outside of...

Deciding what to do with your Zoom Communications stock these days feels a little like trying to tune in to the right frequency, with so many signals flying around. After the wild swings of recent years, you might be wondering if now is the right time to buy, hold, or even walk away. The stock price, lately hovering around $73, has been on a bit of a roller coaster, down just over 10% year-to-date, but up about 7.5% in the past year. That back-and-forth movement says a lot about shifting...

Some Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders may be a little concerned to see that the CFO, Treasurer...

CG Oncology, Inc. announced earnings results for the second quarter and first half of 2025, reporting a net loss of US$41.43 million for the quarter and US$75.88 million for the six months ended June 30, both sharply higher than a year earlier. The company's basic loss per share from continuing operations also increased substantially, highlighting escalating expenses or investment as a key theme in its financial performance. We'll explore how the increased net loss and rising loss per share...

Precigen announced that the US FDA has granted full approval to PAPZIMEOS, the first and only therapy approved for adults with recurrent respiratory papillomatosis (RRP), following positive pivotal clinical trial results showing durable complete responses. This milestone positions PAPZIMEOS as a potential new standard of care for a rare disease previously managed primarily with repeated surgeries lacking curative benefit. We'll explore how the full FDA approval of PAPZIMEOS for RRP reshapes...